Cardiorenal and Humoral Properties of a Novel Direct Soluble Guanylate Cyclase Stimulator BAY 41-2272 in Experimental Congestive Heart Failure
- 11 February 2003
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 107 (5), 686-689
- https://doi.org/10.1161/01.cir.0000055737.15443.f8
Abstract
Background— BAY 41-2272 is a recently introduced novel orally available agent that directly stimulates soluble guanylate cyclase (sGC) and sensitizes it to its physiological stimulator, nitric oxide. To date, its therapeutic actions in congestive heart failure (CHF) remain undefined. We characterized the cardiorenal actions of intravenous BAY 41-2272 in a canine model of CHF and compared it to nitroglycerin (NTG). Methods and Results— CHF was induced by rapid ventricular pacing for 10 days. Cardiorenal and humoral function were assessed at baseline and with administration of 2 doses of BAY 41-2272 (2 and 10 μg · kg −1 · min −1 ; n=8) or NTG (1 and 5 μg · kg −1 · min −1 ; n=6). Administration of 10 μg · kg −1 · min −1 BAY 41-2272 reduced mean arterial pressure (113±8 to 94±6 mm Hg; P P P P P Conclusion— The new sGC stimulator BAY 41-2272 potently unloaded the heart, increased cardiac output, and preserved glomerular filtration rate without activation of the renin-angiotensin-aldosterone system in experimental CHF. These beneficial properties make direct sGC stimulation with BAY 41-2272 a promising new strategy for the treatment of cardiovascular diseases such as CHF.Keywords
This publication has 8 references indexed in Scilit:
- Identification of the enzymatic mechanism of nitroglycerin bioactivationProceedings of the National Academy of Sciences, 2002
- Role of cyclic GMP‐dependent protein kinase in the contractile response to exogenous nitric oxide in rat cardiac myocytesThe Journal of Physiology, 2002
- NO-independent regulatory site on soluble guanylate cyclaseNature, 2001
- The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunctionJournal of the American College of Cardiology, 2000
- Validation of a clinical prediction rule for left ventricular ejection fraction after myocardial infarction in patients ≥ 65 years oldThe American Journal of Cardiology, 1997
- cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase.Proceedings of the National Academy of Sciences, 1996
- Specificity of different organic nitrates to elicit NO formation in rabbit vascular tissues and organs in vivoBritish Journal of Pharmacology, 1995
- The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failureJournal of the American College of Cardiology, 1992